Abstract
ABSTRACT: We evaluated the effectiveness of administration of high-dose busulfan (BU), an alkylating agent with substantial myeloablative but negligible immunosuppressive properties, on the engraftment of congenic normal bone marrow and spleen cells (hematopoietic cell transplantation; HCT) in murine galactosylceramidase deficiency (the twitcher mouse), a model of human sphingolipid storage disease. Untreated mice died with extensive demyelbtatioa and failure to thrive at a median age of 40 d (range, 28–47; n = 51). The life-span of twitcher mice given HCT at age 10 d after 100 mg/kg BU was significantly prolonged (median, 94 d; range, 55–140; n = 17); these animals did not develop the hindlimb paralysis seen in untreated twitchers. Histologic examination of twitcher sciatic nerves after HCT showed remyelinated areas and decreased globoid cell inclusions. Animals given HCT after conditioning with BU had both lymphoid and hematopoietic repopulation with donor cells by 90 d after HCT, as documented by presence of donor glucose phosphate isomerase-1A activity in blood, bone marrow, spleen, and lymph nodes. After BU and HCT, galactosylceramidase activity in livers and spleens of twitcher mice reached 45 and 80% of control, respectively; only modest elevations were observed in kidneys and lymph nodes. Hydrolase activity rose to 20% in the brains and exceeded control values in the sciatic nerves of transplanted twitcher mice, indicating entry of at least some donor-derived cells and/or hydrolase across the blood-brain and blood-nerve barriers after BU and HCT. These observations suggest that, in gene-replacement therapy for human lysosomal storage diseases, administration of BU alone may be sufficient for sustained engraftment of autologous marrow cells into which the specific hydrolase gene has been inserted.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yeager, A., Shinohara, M. & Shinn, C. Hematopoietic Cell Transplantation after Administration of High-Dose Busulfan in Murine Globoid Cell Leukodystrophy (the Twitcher Mouse). Pediatr Res 29, 302–305 (1991). https://doi.org/10.1203/00006450-199103000-00016
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199103000-00016
This article is cited by
-
The role of microglia in human disease: therapeutic tool or target?
Acta Neuropathologica (2014)
-
Effects of Irradiation on the Postnatal Development of the Brain in a Genetic Mouse Model of Globoid Cell Leukodystrophy
Neurochemical Research (2007)
-
Transgenic rescue of Krabbe disease in the twitcher mouse
Gene Therapy (2004)
-
Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations
British Journal of Cancer (1999)